Skip to main content
Non-Melanoma Skin Cancer (NMSC)CancerSkinDrugDevice

What this study is

The primary objective of this study is the evaluation of the efficacy of the tissue oxygen imager based on PpIX DF in differentiating benign skin growth from non-melanoma skin cancer (NMSC).

What's being tested

  • Ameluz 10% Topical Gel

    Intervention · DRUG

    One-time topical application of 10% Ameluz gel for up to 1 hour

  • Protoporphyrin IX

    Intervention · DEVICE

    Tissue oxygen imaging using protoporphyrin IX (PIX), a non-significant risk device.

Study details

Official title
Tissue Oxygen Imager
Sponsor
Dartmouth-Hitchcock Medical Center
Conditions
Non-Melanoma Skin Cancer (NMSC) · Benign Skin Growth
Enrolling
125 people
Starts
2025-11-14
Est. completion
2027-11
Record
View on ClinicalTrials.gov ↗